Rhythm Pharmaceuticals, Inc. $RYTM
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-20
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING1
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO40%
Delay Index: of 5 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +1.4 months). See all sponsors →
Open Rhythm Pharmaceuticals, Inc. on the live radar map → 📅 $RYTM readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Setmelanotide NCT05774756 |
P3 | Active, not recruiting | Hypothalamic Obesity | 143 | 2025-03-18 |
| Setmelanotide NCT06772597 |
P2 | Active, not recruiting | Prader-Willi Syndrome; Obesity | 18 | 2026-11-03 (+9 mo) |
| Setmelanotide NCT06760546 |
P3 | Recruiting | Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form | 39 | 2027-03-13 (+1 mo) |
| Part C: RM-718 NCT06239116 |
P1/2 | Active, not recruiting | Hypothalamic Obesity; Prader-Willi Syndrome | 111 | 2027-05-07 (+22 mo) |
| Bivamelagon NCT07156578 |
P2 | Enrolling by invitation | Hypothalamic Obesity | 25 | 2028-04-15 |